Reynders McVeigh Capital Management LLC Sells 30,453 Shares of Becton, Dickinson and Company $BDX

Key Points

• Reynders McVeigh Capital Management cut its Becton, Dickinson and Company stake by 77.4% in the second quarter, selling 30,453 shares and retaining 8,891 shares valued at approximately $1.345 million.
• Institutional investors own 86.97% of BDX, with notable additions from BlackRock and First Eagle Investment Management. Analysts have a consensus “Hold” rating and an average price target of $187.67.
• BDX reported quarterly revenue of $4.98 billion and adjusted earnings of $3.23 per share, exceeding estimates, and declared a quarterly dividend of $1.05 per share, representing a 2.3% annualized yield.

Reynders McVeigh Capital Management LLC lowered its holdings in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 77.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,891 shares of the medical instruments supplier's stock after selling 30,453 shares during the quarter. Reynders McVeigh Capital Management LLC's holdings in Becton, Dickinson and Company were worth $1,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new position in Becton, Dickinson and Company during the 2nd quarter valued at about $3,721,533,000. First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 15.8% in the second quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier's stock worth $2,090,675,000 after acquiring an additional 1,887,224 shares during the period. Geode Capital Management LLC grew its stake in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Geode Capital Management LLC now owns 6,885,361 shares of the medical instruments supplier's stock worth $1,331,165,000 after acquiring an additional 53,884 shares during the period. Auto Owners Insurance Co raised its holdings in shares of Becton, Dickinson and Company by 22,225.2% during the fourth quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier's stock valued at $790,079,000 after purchasing an additional 40,528,680 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Becton, Dickinson and Company during the fourth quarter valued at approximately $734,321,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have commented on BDX. Bank of America lifted their target price on shares of Becton, Dickinson and Company from $185.00 to $200.00 and gave the stock a "neutral" rating in a research report on Monday, August 31st. UBS Group initiated coverage on Becton, Dickinson and Company in a report on Tuesday, July 28th. They issued a "buy" rating and a $190.00 price target on the stock. Wells Fargo & Company upped their price target on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an "equal weight" rating in a research note on Friday, August 7th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a "sector perform" rating in a research report on Thursday, August 13th. Finally, The Goldman Sachs Group lowered their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a "neutral" rating on the stock in a report on Wednesday, May 27th. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $187.67.

Becton, Dickinson and Company Price Performance

Shares of NYSE:BDX traded up $2.87 during mid-day trading on Tuesday, reaching $185.78. The stock had a trading volume of 2,087,411 shares, compared to its average volume of 2,558,622. The business's 50 day moving average price is $173.06 and its 200 day moving average price is $160.49. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The company has a market cap of $51.19 billion, a P/E ratio of 55.96, a price-to-earnings-growth ratio of 12.53 and a beta of 0.21. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The business had revenue of $4.98 billion for the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter in the previous year, the company posted $3.68 EPS. The company's revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. The ex-dividend date is Wednesday, September 9th. This represents a $4.20 dividend on an annualized basis and a yield of 2.3%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 126.51%.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business's stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total value of $768,120.00. Following the completion of the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $20,380,155. The trade was a 3.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the transaction, the executive vice president directly owned 13,172 shares in the company, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,005 shares of company stock valued at $1,423,580 in the last quarter. Corporate insiders own 0.40% of the company's stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells products used by healthcare providers, researchers and pharmaceutical companies. Founded in 1897 by Maxwell Becton and Fairleigh Dickinson, the company is headquartered in Franklin Lakes, New Jersey.

BD's products support medication delivery, infection prevention, diagnostics and surgical care. Its portfolio includes needles, syringes, injection devices, infusion products, medication-management systems, specimen-collection products, laboratory instruments and diagnostic technologies.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.